Orexo AB (publ) (FRA:C5G)

Market Cap	98.10M +65.4%
Revenue (ttm)	49.16M -8.8%
Net Income	-18.25M
EPS	-0.53
Shares Out	n/a
PE Ratio	n/a
Forward PE	4.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	85
Open	2.795
Previous Close	2.820
Day's Range	2.795 - 2.795
52-Week Range	1.092 - 3.825
Beta	n/a
RSI	48.27
Earnings Date	Feb 5, 2026

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 104
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C5G

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK